June 03, 2026 a 07:46 am

MDT: Dividend Analysis - Medtronic plc

📊 Overview

Medtronic operates within the Health Care sector, providing a stable dividend yield of 3.26%. The company currently dispenses 2.79 USD per share with a robust dividend history extending over 45 years, highlighting its commitment to returning value to shareholders. Importantly, the firm has avoided any recent cuts or suspensions, indicating a reliable income stream.

Metric	Value
Sector	Health Care
Dividend yield	3.26%
Current dividend per share	2.79 USD
Dividend history	45 years
Last cut or suspension	None

📈 Dividend History

Medtronic has consistently rewarded its shareholders with increasing dividends, which underscores its financial resilience and commitment to shareholders. Such a record contributes positively to investor confidence, making it an attractive proposition in the market.

Year	Dividend per Share (USD)
2026	0.71
2025	2.83
2024	2.79
2023	2.75
2022	2.67

📉 Dividend Growth

The modest but continuous enhancement in dividends over the three and five-year periods suggests a steady growth trajectory. This gradual appreciation is pivotal for long-term investors seeking both income and growth potential as it signals consistent financial health and operational efficiency.

Time	Growth
3 years	1.96%
5 years	4.42%

The average dividend growth is 4.42% over 5 years. This shows moderate but steady dividend growth.

✅ Payout Ratio

Payout ratios offer critical insights into the sustainability of a company's dividend payments. A 77.57% EPS-based payout ratio and a 66.25% FCF-based ratio indicate a relatively high but still manageable dividend payout, suggesting cautious optimism provided earnings and cash flows remain stable.

Key figure	Ratio
EPS-based	77.57%
Free cash flow-based	66.25%

The payout ratios reflect an above-average distribution of profits, which may limit future raises but remain tenable under current profit levels, underscoring Medtronic's capacity to maintain its dividend strategy.

📊 Cashflow & Capital Efficiency

Evaluating cash flow efficiency and capital allocation is fundamental for assessing a company's ability to cover dividends and reinvest for growth. Medtronic's solid free cash flow yield and operating cash flow ratios demonstrate effective financial oversight and fiscal prudence.

Metric	2023	2024	2025
Free Cash Flow Yield	5.71%	4.91%	4.79%
Earnings Yield	4.88%	3.47%	4.31%
CAPEX to Operating Cash Flow	25.74%	23.38%	26.39%
Stock-based Compensation to Revenue	1.27%	1.21%	1.28%
Free Cash Flow / Operating Cash Flow Ratio	73.61%	76.62%	73.61%

Medtronic's strategic management of its capital and cash flow ensures continued financial health and supports ongoing dividend payments, striking a balance between rewarding investors and positioning for future opportunities.

📈 Balance Sheet & Leverage Analysis

Understanding leverage is pivotal in determining a company's risk and ability to meet obligations. Medtronic's debt metrics reflect moderate leverage, suggesting judicious use of debt to finance its operations without overextending financially.

Metric	2023	2024	2025
Debt-to-Equity	0.47	0.50	0.59
Debt-to-Assets	0.27	0.28	0.31
Debt-to-Capital	0.32	0.33	0.37
Net Debt to EBITDA	2.62	2.89	2.88
Current Ratio	2.39	2.03	1.85
Quick Ratio	1.81	1.55	1.42
Financial Leverage	1.77	1.79	1.91

The firm's manageable leverage ratios indicate robust financial stability, ensuring adequate liquidity and capability to service debt, thus protecting shareholder interests and enhancing investor appeal.

✅ Fundamental Strength & Profitability

Profitability metrics such as ROE and ROA provide insight into the firm's efficiency in generating profits. Medtronic's returns on equity and assets underscore a proficient use of equity financing and effective management of its asset base.

Metric	2023	2024	2025
Return on Equity	7.30%	7.32%	9.71%
Return on Assets	4.13%	4.09%	5.09%
Margins: Net	12.03%	11.36%	13.90%
EBIT Margin	19.21%	17.17%	18.96%
EBITDA Margin	27.85%	25.35%	27.49%
Gross Margin	65.67%	65.34%	65.52%
Research & Development to Revenue	8.63%	8.45%	8.81%

Medtronic's strong margin profile reflects robust profitability, supporting its ability to maintain competitive R&D spending, which is crucial for sustained innovation and market leadership.

📈 Price Development

🗣️ Dividend Scoring System

Category	Score	Rating
Dividend yield	4
Dividend Stability	5
Dividend growth	3
Payout ratio	3
Financial stability	4
Dividend continuity	5
Cashflow Coverage	4
Balance Sheet Quality	5

⚠️ Rating

Medtronic's overall dividend profile is robust, rendering it an appealing option for those seeking a combination of stability and modest growth in dividend income. The balance between its sustainable payout ratios, strong revenue profiles from disciplined cash flow management, and commendable financial stability reinforces its attractiveness. Thus, Medtronic is a favorable buy for dividend-centric portfolios.